Posted by Michael Wonder on 10 Jan 2025
Erdafitinib for the treatment of patients with metastatic or unresectable FGFR altered urothelial cancer
9 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use of erdafitinib in the NHS in England.
For the time being, erdafitinib is not recommended for the treatment of adults with unresectable or metastatic urothelial cancer with susceptible FGFR3 genetic alterations after at least one line of treatment for unresectable or metastatic cancer that included a programmed death receptor-1 (PD-1/PD-L1) antagonist.
